e-learning
resources
ERJ
2011
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Microbial evaluation of proton-pump inhibitors and the risk of pneumonia
Meijvis S.C.A., Cornips M.C.A., Voorn G.P., Souverein P.C., Endeman H., Biesma D.H., Leufkens H.G.M., van de Garde E.M.W.
Source:
Eur Respir J 2011; 38: 1165-1172
Journal Issue:
November
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Meijvis S.C.A., Cornips M.C.A., Voorn G.P., Souverein P.C., Endeman H., Biesma D.H., Leufkens H.G.M., van de Garde E.M.W.. Microbial evaluation of proton-pump inhibitors and the risk of pneumonia. Eur Respir J 2011; 38: 1165-1172
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Middle-long term pulmonary abnormalities after severe COVID-19 pneumonia which required invasive ventilation
Related content which might interest you:
The risk of community-acquired pneumonia and the use of statins, ACE inhibitors and gastric acid suppressants
Source: Annual Congress 2008 - Infectious lung diseases including tuberculosis
Year: 2008
Microbial evaluation of proton pump inhibitors and the risk of pneumonia
Source: Annual Congress 2011 - Respiratory epidemiology: genetics and modifiable risk factors
Year: 2011
Inhaled drugs as risk factors for community-acquired pneumonia
Source: Eur Respir J 2010; 36: 1080-1087
Year: 2010
Aspiration risks factors, microbiology and empiric antibiotics for patients hospitalized with community-acquired pneumonia
Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice
Year: 2020
Pharmacokinetic optimisation of β-lactams for the treatment of ventilator-associated pneumonia
Source: Eur Respir Rev 2007; 16: 45-49
Year: 2007
Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia
Source: Eur Respir J 2009; 33: 153-159
Year: 2009
Combination versus monotherapy for nosocomial pneumonia
Source: Eur Respir Rev 2007; 16: 50-55
Year: 2007
Are corticosteroids useful in community-acquired pneumonia?
Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia
Year: 2006
Inhaled drugs as risk factors for community-acquired pneumonia
Source: Annual Congress 2010 - The spectrum of lower respiratory tract infections: risk factors of poor outcome and diagnostic tools
Year: 2010
Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia
Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants
Year: 2015
Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia
Source: Eur Respir J, 50 (3) 1602306; 10.1183/13993003.02306-2016
Year: 2017
The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 733s
Year: 2006
Angiotensin-converting enzyme insertion/deletion polymorphism and risk and outcome of pneumonia
Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia
Year: 2007
Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia
Source: Eur Respir J 2004; 24 : 644-648
Year: 2004
Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia
Source: Eur Respir J 2008; 31: 611-617
Year: 2008
Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia
Source: Eur Respir J 2010; 36: 128-134
Year: 2010
The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis
Source: Eur Respir J 2007; 30: 525-531
Year: 2007
Costs of treatment of hospitalised community-acquired pneumonia from the hospitals’ perspective – a prospective study comparing moxifloxacin with other antibiotic treatment alternatives
Source: Eur Respir J 2004; 24: Suppl. 48, 185s
Year: 2004
The risk of community-acquired pneumonia in children using gastric acid suppressants
Source: Eur Respir J, 58 (4) 2003229; 10.1183/13993003.03229-2020
Year: 2021
Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia
Source: Eur Respir J 2011; 37: 1332-1339
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept